Similar articles

• Short-course beta-lactam treatment for community-acquired pneumonia.

  Stralin K, Sjöberg L, Holmberg H. Stralin K, et al. Clin Infect Dis. 2004 Mar 1;38(5):766-7. doi: 10.1086/381761. Clin Infect Dis. 2004. PMID: 14986269 No abstract available.
• Hospitalized community-acquired pneumonia due to Streptococcus pneumoniae: Has resistance to antibiotics decreased?

  Vallès X, Marcos A, Pinart M, Piñer R, Marco F, Mensa JM, Torres A. Vallès X, et al. Chest. 2006 Sep;130(3):800-6. doi: 10.1378/chest.130.3.800. Chest. 2006. PMID: 16963678
• Role of beta-lactam agents in the treatment of community-acquired pneumonia.

  Garau J. Garau J. Eur J Clin Microbiol Infect Dis. 2005 Feb;24(2):83-99. doi: 10.1007/s10096-005-1287-9. Eur J Clin Microbiol Infect Dis. 2005. PMID: 15696306 Review.
• Streptococcus pneumoniae: does antimicrobial resistance matter?

  Lynch JP 3rd, Zhanel GG. Lynch JP 3rd, et al. Semin Respir Crit Care Med. 2009 Apr;30(2):210-38. doi: 10.1055/s-0029-1202939. Epub 2009 Mar 18. Semin Respir Crit Care Med. 2009. PMID: 19296420 Review.
• [New quinolones for the treatment of community-acquired pneumonia--contra].

  Egger M. Egger M. Dtsch Med Wochenschr. 2003 May 9;128(19):1071. doi: 10.1055/s-2003-39105. Dtsch Med Wochenschr. 2003. PMID: 12736860 German. No abstract available.